文献速递神经核医学放射性药物与辐射防护

动脉内给药后纳米抗体与PAMAM树枝状大分子脑摄取差异的PET研究

PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-06-03

该研究在小鼠中比较了经颈动脉与尾静脉给予⁸⁹Zr标记纳米抗体和PAMAM树枝状大分子后的脑摄取。静脉给药时两者脑内积聚均可忽略;动脉给药时纳米抗体脑摄取显著升高,渗透性开放血脑屏障后进一步增强,24小时仍保留初始摄取的一半,而树枝状大分子动脉给药后脑内积聚差并于1小时内完全清除。

要点

  • 静脉给药时纳米抗体与树枝状大分子脑内积聚均可忽略。
  • 动脉给药纳米抗体脑摄取显著升高,渗透性开放血脑屏障后进一步增强。
  • 动脉给药树枝状大分子脑内积聚差,1小时内完全清除。

核心结论

  • 动脉内递送纳米抗体可能是需要延长颅内滞留的中枢神经系统疾病的有吸引力的治疗平台。

研究设计与样本

  • 在小鼠中比较颈动脉与尾静脉输注⁸⁹Zr标记纳米抗体和PAMAM树枝状大分子,血脑屏障完整或甘露醇渗透性开放,动态PET监测30分钟,输注后1小时和24小时全身PET-CT,离体生物分布验证。

主要发现

  • 静脉给予⁸⁹ZrNB(DFO)₂和⁸⁹ZrG4(DFO)₃(Bdiol)₁₁₀时,无论血脑屏障状态和渗透性开放时机,脑内积聚均可忽略。
  • 动脉给予⁸⁹ZrNB(DFO)₂显著增加脑摄取,预先渗透性开放血脑屏障后进一步增强,24小时后保留初始脑摄取的一半。
  • 动脉给予⁸⁹ZrG4(DFO)₃(Bdiol)₁₁₀初始脑内积聚差,给药后1小时内完全清除。
  • 离体生物分布结果与PET-CT结果一致。

临床怎么用

  • 动脉内递送纳米抗体可能适用于需要延长颅内滞留的中枢神经系统疾病治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We have recently shown that intracerebral delivery of an anti-VEGF monoclonal antibody bevacizumab using an intra-arterial (IA) infusion is more effective than intravenous administration. While antibodies are quickly emerging as therapeutics, their disadvantages such as large size, production logistics and immunogenicity motivate search for alternatives. Thus we have studied brain uptake of nanobodies and polyamidoamine (PAMAM) dendrimers. METHODS: Nanobodies were conjugated with deferoxamine (DFO) to generate NB(DFO)2. Generation-4 PAMAM dendrimers were conjugated with DFO, and subsequently primary amines were capped with butane-1,2-diol functionalities to generate G4(DFO)3(Bdiol)110. Resulting conjugates were radiolabeled with zirconium-89. Brain uptake of 89ZrNB(DFO)2 and 89ZrG4(DFO)3(Bdiol)110 upon carotid artery vs tail vein infusions with intact BBB or osmotic blood-brain barrier opening (OBBBO) with mannitol in mice was monitored by dynamic positron emission tomography (PET) over 30 min to assess brain uptake and clearance, followed by whole-body PET-CT (computed tomography) imaging at 1 h and 24 h post-infusion (pi). Imaging results were subsequently validated by ex-vivo biodistribution. RESULTS: Intravenous administration of 89ZrNB(DFO)2 and 89ZrG4(DFO)3(Bdiol)110 resulted in their negligible brain accumulation regardless of BBB status and timing of OBBBO. Intra-arterial (IA) administration of 89ZrNB(DFO)2 dramatically increased its brain uptake, which was further potentiated with prior OBBBO. Half of the initial brain uptake was retained after 24 h. In contrast, IA infusion of 89ZrG4(DFO)3(Bdiol)110 resulted in poor initial accumulation in the brain, with complete clearance within 1 h of administration. Ex-vivo biodistribution results reflected those on PET-CT. CONCLUSIONS: IA delivery of nanobodies might be an attractive therapeutic platform for CNS disorders where prolonged intracranial retention is necessary.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lesniak WG, Chu C, Jablonska A, et al. PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration. Eur J Nucl Med Mol Imaging. 2019. PMID: 31161257. doi:10.1007/s00259-019-04347-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。